The Dow Jones Industrial Average fell 382.15 points, or 0.86%, to 43,910.98, the S&P 500 lost 17.36 points, or 0.29%, to ...

Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a ...

Shares of pharmaceutical giant Amgen (AMGN) are attempting to bounce back after suffering a steep drop of 7.1% yesterday.

Bell reported relationships with the Dementia Australia Research Foundation, GlaxoSmithKline Supported Studies Programme, ...

In this photo illustration, Amgen logo is displayed on a smartphone with a S&P ... [+] index website background. (Photo ...

Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...

Thomas also held leadership posts with Novartis, Bristol-Myers Squibb, Beigene, GSK and Amgen. Thomas received a bachelor's ...

Amgen stock tumbled late Tuesday on a report its high-profile weight-loss shot, MariTide, could be linked to bone mineral ...

Analysts have set 12-month price targets for Amgen, revealing an average target of $349.0, a high estimate of $405.00, and a ...

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

On Tuesday, a Cantor analyst wrote that additional data from Amgen’s experimental weight loss injection, MariTide, suggests a ...

Amgen (AMGN) stock spiked after the company ruled out out bone density concerns linked to obesity drug MariTide, following a ...